Assessing cardiovascular risk in cancer patients: opportunities and challenges
- PMID: 32718234
- PMCID: PMC8005777
- DOI: 10.1177/2047487320943002
Assessing cardiovascular risk in cancer patients: opportunities and challenges
Conflict of interest statement
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Comment on
-
Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry.Eur J Prev Cardiol. 2022 May 6;29(6):859-868. doi: 10.1093/eurjpc/zwaa034. Eur J Prev Cardiol. 2022. PMID: 33624069
References
-
- Centers for Disease Control and Prevention. Leading Causes of Death. (2017). https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm (2017; accessed 3 July 2020).
-
- European Society of Cardiology. Clinical Practice Guidelines. (2020). https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines (2020; accessed 3 July 2020).
-
- Caro-Códon J, López Fernández T, Álvarez-Ortega C, et al.Cardiovascular risk factors during cancer treatment. prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur J Prev Cardiol 2020. - PubMed
